NAVB vs. CRF

In the year-to-date period, NAVB achieves a -0.00% return, which is significantly lower than CRF's 4.15% return. Over the past 10 years, NAVB has underperformed CRF with an annualized return of -71.97%, while CRF has yielded a comparatively higher 12.36% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Navidea Biopharmaceuticals, Inc. (NAVB) and Cornerstone Total Return Fund, Inc. (CRF). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NAVB Sharpe Ratio is -0.09, which is lower than the CRF Sharpe Ratio of 2.33. The chart below compares the historical Sharpe Ratios of NAVB and CRF, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

NAVB has not paid dividends to shareholders, while CRF's dividend yield for the trailing twelve months is around 14.12%.

The maximum NAVB drawdown since its inception was -100.00%, which is greater than CRF's maximum drawdown of -78.18%. Use the drawdown chart below to compare losses from any high point for NAVB and CRF. For additional features, visit the drawdowns tool.

Navidea Biopharmaceuticals, Inc. (NAVB) has a higher volatility of 333.68% compared to Cornerstone Total Return Fund, Inc. (CRF) at 4.49%. This indicates that NAVB's price experiences larger fluctuations and is considered to be riskier than CRF based on this measure. The chart below showcases a comparison of their rolling one-month volatility.